CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma

CAR-T Therapy in Multiple Myeloma | Dallas Roundtable November 2, 2024Подробнее

Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Mu...Подробнее

Advice for physicians when managing bispecific antibody treatment for patients with myelomaПодробнее

BCMA-Directed Therapy in Multiple Myeloma: Assessing the Clinical ImpactПодробнее

Toxicity Management: CAR-Ts Versus Bispecific T-Cell EngagersПодробнее

An overview of the toxicities associated with immunotherapy in multiple myelomaПодробнее

Myeloma Matters Podcast | Immunotherapy Side EffectsПодробнее

Multiple Myeloma Treatment: Induction, CAR T, Managing Side Effects and Maintaining Quality of LifeПодробнее

Prevention and Management of Bispecific Antibody Associated Adverse Events in Multiple MyelomaПодробнее

Hitting the BCMA Target in Multiple MyelomaПодробнее

What are the side effects of CAR-T cell therapy? #myelomaПодробнее

Multiple Myeloma - 2023 Best of Hematology ConferenceПодробнее

Top Doctor & Patient Talk Game Changing Cancer Treatments: How Close is a Cure? (Multiple Myeloma)Подробнее

Betting on BCMA Therapy in Multiple MyelomaПодробнее

Initial Safety Results for Phase 2 MagnetisMM-3 Trial Presented at ASCO 2022Подробнее

Clinical Activity of BMS-986393, a CAR T cell therapy directed at GPRC5D, in Pts with RRMMПодробнее

The Latest Insights on Immune Therapies in Myeloma | 2023 IMF Patient and Family SeminarПодробнее

A 2023 Update on CAR-T Therapy in Myeloma with Dr. Craig HofmeisterПодробнее

What is ICANS?Подробнее